HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People On The Move: Appointments At Kenvue, Futura, Mayoly Spindler

Executive Summary

A round-up of the latest appointments in Europe's consumer health market: Kenvue promotes Lawson to expanded role; Futura adds Davis as non-executive director; and Mayoly Spindler hires Morlie to lead Italy operation.

You may also be interested in...



US Q4 Consumer Health Earnings Preview: Supply Chain Disruption Returns, Opill Launch Waits

Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.

Female Sexual Dysfunction, China, Next On The Agenda For Eroxon Creator Futura

Drug-free erectile dysfunction “stimgel” creator Futura wants to see if the technology underpinning Eroxon can be applied to female sexual dysfunction. Breaking into China is also high up on the agenda for the UK-based R&D company's CEO James Barder, he reveals in this exclusive interview.

France’s Mayoly Spindler Set To Acquire Ipsen’s Consumer Business

Mayoly Spindler is stepping up its presence in the self-care market with the acquisition of Ipsen's Consumer Healthcare business, which has been under strategic review for the past year.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel